Description: <p><b>Caffeic Acid Phenethyl Ester (CAPE)</b> — CAPE is a propolis-derived phenolic ester and bioactive honeybee-hive constituent with pleiotropic anti-inflammatory and antineoplastic signaling effects. It is best classified as a natural polyphenolic small molecule and experimental adjunct candidate rather than an approved anticancer drug. Standard abbreviations include CAPE; common chemical naming includes caffeic acid phenethyl ester and phenethyl caffeate. CAPE is most strongly associated with poplar-type propolis chemistry, but it is also available as an ingredient in some dietary-supplement products. Current oncology relevance remains preclinical to early translational, with growing interest in chemosensitization and radiosensitization but no established cancer indication.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>NF-κB pathway inhibition with downstream suppression of pro-inflammatory and pro-survival transcription</li>
<li>PI3K/Akt and p70S6K network suppression with reduced proliferation and survival signaling</li>
<li>Wnt/β-catenin/TCF inhibition with reduced cyclin D1 and c-MYC signaling</li>
<li>Anti-invasive / anti-metastatic modulation via reduced MMP expression and related motility programs</li>
<li>Mitochondrial and metabolic stress reprogramming, including membrane depolarization and a shift toward glycolysis in some tumor models</li>
<li>Chemo/radiosensitization in selected models, including autophagy inhibition and context-dependent enhancement of cytotoxic therapy</li>
<li>Secondary redox and cytoprotective modulation, including ROS buffering or oxidative stress induction depending on model and exposure</li>
<li>Secondary eicosanoid/inflammatory enzyme effects, including COX-2 and lipoxygenase-related signaling suppression</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Oral translation is constrained by poor aqueous solubility, limited absorption, esterase-sensitive disposition, and substantial hydrolysis to caffeic acid in vivo. Rat PK work supports measurable exposure after oral dosing, but CAPE analogues with improved permeability outperform parent CAPE. Formulation strategies are therefore mechanistically relevant for systemic use.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many direct anticancer studies use roughly 10–60 μM exposure, with some effects emerging near or above this range; those concentrations may exceed or stress the upper edge of practical systemic exposure with simple oral delivery. Tumor-directed claims should therefore be weighted more heavily when supported by in vivo xenograft, radiosensitization, or formulation-enabled data rather than cell culture alone.</p>
<p><b>Clinical evidence status:</b> Predominantly preclinical with in vitro, xenograft, and ex vivo support; small translational signals exist for radiosensitization/radioprotection concepts, but there is no established oncology trial program or approved cancer use for CAPE itself.</p>
<h3>CAPE — Cancer vs Normal Cell Pathway Map</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>NF-κB inflammatory transcription</td>
<td>NF-κB ↓; inflammatory/pro-survival gene programs ↓</td>
<td>Inflammatory stress ↓</td>
<td>P/R</td>
<td>Anti-inflammatory and anti-survival signaling suppression</td>
<td>Most canonical CAPE axis; supported by classic mechanistic work and newer radiosensitization studies. Central for cytokine, survival, and stress-response attenuation.</td>
</tr>
<tr>
<td>2</td>
<td>PI3K/Akt / p70S6K / c-MYC</td>
<td>Akt ↓; p70S6K ↓; c-MYC ↓; proliferation ↓</td>
<td>↔ / protective (context-dependent)</td>
<td>R/G</td>
<td>Cytostatic and pro-apoptotic pressure</td>
<td>Strong relevance in prostate and NSCLC models; appears therapeutically leveraged in combination settings.</td>
</tr>
<tr>
<td>3</td>
<td>Wnt / β-catenin / TCF</td>
<td>β-catenin ↓; nuclear β-catenin ↓; cyclin D1 ↓; c-MYC ↓</td>
<td>↔</td>
<td>R/G</td>
<td>Growth arrest and apoptosis support</td>
<td>Well supported in colon cancer models; helps explain antiproliferative and differentiation-related effects.</td>
</tr>
<tr>
<td>4</td>
<td>MMP invasion / metastasis axis</td>
<td>MMP-2 ↓; MMP-9 ↓; MT1-MMP ↓; invasion ↓</td>
<td>ECM injury/inflammation ↓ (context-dependent)</td>
<td>R/G</td>
<td>Anti-invasive and anti-metastatic effect</td>
<td>Useful translational axis because it links inflammatory signaling to motility and matrix remodeling.</td>
</tr>
<tr>
<td>5</td>
<td>Mitochondria / metabolic reprogramming</td>
<td>Mitochondrial membrane potential ↓; respiration shift toward glycolysis</td>
<td>Potential radioprotective anti-inflammatory support in tissue slices</td>
<td>P/R</td>
<td>Stress amplification and therapeutic-window modulation</td>
<td>Recent lung data suggest CAPE can destabilize tumor bioenergetics while dampening inflammatory injury signals in normal tissue contexts.</td>
</tr>
<tr>
<td>6</td>
<td>Autophagy / chemosensitization</td>
<td>Autophagy ↓; oxaliplatin sensitivity ↑</td>
<td>↔</td>
<td>R/G</td>
<td>Adjunct sensitization to therapy</td>
<td>Now a meaningful secondary axis; 2024 colon-cancer work supports autophagy inhibition as one mechanism of drug sensitization.</td>
</tr>
<tr>
<td>7</td>
<td>Radiosensitization</td>
<td>RadioS ↑ (adenocarcinoma-selective in some models)</td>
<td>Radiation-associated inflammatory injury ↓ (context-dependent)</td>
<td>R/G</td>
<td>Potential therapeutic-window expansion</td>
<td>Important emerging translational niche rather than a universal CAPE effect; appears histology- and context-dependent.</td>
</tr>
<tr>
<td>8</td>
<td>ROS / NRF2 redox modulation (secondary)</td>
<td>ROS ↔ / ↑ / ↓ (context-dependent); NRF2 ↔ / ↑ (secondary)</td>
<td>ROS injury ↓; cytoprotective antioxidant tone ↑ (context-dependent)</td>
<td>P/R/G</td>
<td>Redox buffering or oxidative stress depending on setting</td>
<td>CAPE is not best treated as a simple antioxidant. In tumors it may contribute to stress and death signaling, while in normal tissue it may support anti-inflammatory/radioprotective responses.</td>
</tr>
<tr>
<td>9</td>
<td>COX-2 / lipoxygenase inflammatory eicosanoids</td>
<td>COX-2-related signaling ↓; LOX-related signaling ↓</td>
<td>Inflammatory eicosanoid tone ↓</td>
<td>P/R</td>
<td>Inflammation and microenvironment restraint</td>
<td>Mechanistically plausible and historically supported, but generally more secondary than NF-κB/Akt/β-catenin in oncology framing.</td>
</tr>
<tr>
<td>10</td>
<td>Clinical Translation Constraint</td>
<td>Bioavailability ↓; exposure consistency ↓</td>
<td>Systemic delivery limitations ↑</td>
<td>—</td>
<td>Formulation-limited translation</td>
<td>Poor solubility, hydrolysis, and variable absorption limit confidence that common oral dosing reproduces stronger in vitro anticancer concentrations.</td>
</tr>
</table>
<p><b>TSF legend:</b> P: 0–30 min; R: 30 min–3 hr; G: >3 hr</p>